YOLFTbeta
INmune Bio Inc

INmune Bio Inc

INMB · NASDAQ · Healthcare / Biotechnology

1.05USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.05
Open1.06
Day Range1.02 – 1.09
52-Week Range1.09 – 2.60
Volume476.50K
Market Cap55.51M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.61
Dividend Yield0.00%
Beta0.94
50-Day Avg2.11
200-Day Avg1.64

About

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. David J. Moss M.B.A.
  • Employees21
  • Headquarters225 NE Mizner Blvd., Boca Raton, FL, United States, 33432, USA
  • Websitehttps://www.inmunebio.com

Leadership

  • Mr. David J. Moss M.B.A.President, CEO, Treasurer, Secretary & Director · b. 1970
  • Mr. Cory Randall EllspermannInterim Chief Financial Officer · b. 1973
  • Dr. Mark William Lowdell Ph.D.Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer · b. 1963
  • Mr. Daniel Frederick CarlsonHead of Investor Relations · b. 1967
  • Mr. Joshua S. Schoonover Esq.General Counsel

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000077.69M10.92K181.00K374.00K155.00K14.00K50.00K
Growth (%)------99.99%+1558.12%+106.63%-58.56%-90.97%+257.14%
Cost of Revenue0000-------
Gross Profit000077.69M10.92K181.00K374.00K155.00K14.00K50.00K
Gross Margin----100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense48.87K227.00K981.00K12.44M85.44M12.24M29.33M26.32M29.90M42.65M30.92M
Operating Income-48.87K-227.00K-981.00K-12.44M-7.76M-12.23M-29.15M-25.95M-29.74M-42.63M-30.87M
Operating Margin-----9.98%-112016.09%-16106.63%-6938.77%-19187.74%-304535.71%-61738.00%
EBITDA146.60K-50.00K149.99K-12.44M-7.68M-12.23M-30.34M-27.30M-267.00K-41.53M-45.85M
EBITDA Margin-----9.88%-112016.09%-16762.43%-7299.20%-172.26%-296635.71%-91698.00%
Net Income-48.87K-277.00K-831.00K-12.44M-7.68M-12.10M-30.34M-28.65M-30.01M-42.08M-45.93M
Net Income Margin-----9.88%-110838.76%-16762.43%-7659.63%-19360.00%-300585.71%-91866.00%
R&D101.50K101.50K435.36K1.11M3.28M5.92M20.54M17.07M20.27M33.17M20.66M
R&D as % of Total Revenue----4.22%54209.37%11349.72%4563.37%13079.35%236900.00%41318.00%
Interest Expense0000001.19M1.35M---
Interest Expense % of Total Revenue----0.00%0.00%655.80%360.43%---

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.88K451.61K18.41M17.36M24.47M40.66M99.94M81.80M57.00M39.56M32.35M
Total Liabilities30.75K600.81K309.72K823.77K860.54K1.90M19.72M21.69M18.86M7.46M8.83M
Total Equity-18.87K-149.20K18.10M16.54M23.61M38.75M80.22M60.10M38.14M32.10M23.52M
Cash11.88K141.66K1.37M186.20K7.00M21.97M74.81M52.15M35.85M20.92M24.75M
Total Debt-350.00K--168.45K160.00K15.23M15.31M10.44M384.00K1.03M
Net Debt-11.88K208.34K-1.37M-186.20K-6.83M-21.81M-59.58M-36.84M-25.41M-20.54M-23.72M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-18.12K-317.38K-761.83K-2.06M-5.38M-8.94M-28.50M-22.69M-11.98M-33.36M-22.58M
Investing Cash Flow-100.00K-100.00K-100.00K-15.00M-15.00M-15.00M-15.00M----1.04M
Financing Cash Flow30.00K450.00K2.06M900.00K12.21M23.90M96.36M729.00K-4.22M18.21M27.61M
Capital Expenditure00100.00K00415.00M0001.04M
Free Cash Flow-18.12K-317.38K-861.83K-2.06M-5.38M-8.94M-43.50M-22.69M-11.98M-33.36M-23.62M
FCF to OCF100.00%100.00%113.13%100.00%100.00%100.00%152.62%100.00%100.00%100.00%104.61%

Earnings

Report DateDec 1, 2017Jun 13, 2018Aug 30, 2018Dec 21, 2018Mar 29, 2019May 15, 2019Aug 9, 2019Nov 8, 2019Mar 11, 2020May 14, 2020Aug 5, 2020Nov 5, 2020Mar 4, 2021May 5, 2021Aug 4, 2021Nov 3, 2021Mar 3, 2022May 5, 2022Aug 3, 2022Nov 2, 2022Mar 2, 2023May 3, 2023Aug 7, 2023Nov 1, 2023Mar 28, 2024May 9, 2024Aug 1, 2024Oct 31, 2024Mar 26, 2025May 8, 2025Aug 7, 2025Oct 30, 2025Dec 31, 2025May 7, 2026Aug 6, 2026Oct 29, 2026
EPS Estimate0.000.000.000.00-0.19-0.19-0.20-0.19-0.25-0.21-0.23-0.17-0.31-0.28-0.34-0.40-0.58-0.60-0.47-0.52-0.48-0.02-0.38-0.40-0.44-0.52-0.62-0.49-0.54-0.45-0.37-0.32-0.27-0.18-0.20-0.18
EPS Actual-0.03-0.25-0.55-0.04-0.21-0.20-0.19-0.28-0.22-0.19-0.20-0.36-0.26-0.32-0.44-0.55-0.55-0.39-0.38-0.43-0.32-0.36-0.36-0.48-0.47-0.61-0.50-0.60-0.40-0.43-0.34-0.24-0.18-0.20-0.05-
Surprise-----10.53%-5.26%5.00%-47.37%12.00%9.52%13.04%-111.76%16.13%-14.29%-29.41%-37.50%5.17%35.00%19.15%17.31%33.33%-1700.00%5.26%-20.00%-6.82%-17.31%19.35%-22.45%25.93%4.44%8.11%25.00%33.33%-11.11%75.00%-
Timing----After-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap55.51M
Enterprise Value38.50M
Trailing P/E0.00
Forward P/E0.00
Price / Sales760.34
Price / Book2.73
EPS-0.61
Book Value0.736
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-30.79M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-74.82%
Return on Assets-39.12%
Shares Outstanding27.75M
Shares Float23.30M
Beta0.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 7.00
  • Strong Buy
    2
  • Buy
    3

Ownership Breakdown

Institutions
15.56%
Insiders
10.75%
Retail / Other
73.69%

Top Institutional Holders

  • BlackRock Inc
    1.19M4.30%
  • Vanguard Capital Management, LLC
    687.01K2.48%
  • Geode Capital Management, LLC
    494.97K1.78%
  • State Street Corp
    290.88K1.05%
  • AQR Capital Management LLC
    270.32K0.97%
  • UBS Group AG
    253.34K0.91%
  • The Goldman Sachs Group Inc
    231.59K0.83%
  • Susquehanna International Group, LLP
    194.39K0.70%
  • Northern Trust Corp
    184.22K0.66%
  • Dauntless Investment Group, LLC
    183.48K0.66%
  • Millennium Management LLC
    159.56K0.57%
  • Vanguard Portfolio Management, LLC
    129.22K0.47%
  • Vanguard Fiduciary Trust Co
    123.18K0.44%
  • Westside Investment Management, Inc.
    108.30K0.39%
  • Citadel Advisors Llc
    106.23K0.38%
  • GSA Capital Partners LLP
    81.99K0.30%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    490.27K1.77%
  • Fidelity Extended Market Index
    189.55K0.68%
  • iShares Micro-Cap ETF
    81.05K0.29%
  • Abante Quant Value FI
    80.26K0.29%